Fundamental and clinical studies of grepafloxacin in respiratory infection
スポンサーリンク
概要
- 論文の詳細を見る
The antimicrobial effects of a new quinolone antimicrobial drug, grepafloxacin (GPFX), on respiratory pathogens as well as its clinical effects and utility were assessed as follows:<BR>The measured MICs of GPFX of 82 isolated strains in respiratory infections were: 0.1 μg/ml for 10 strains of <I>Staphylococcus aureus</I>, 0.39 μg/ml for 17 strains of <I>Streptococcus pneumoniae</I> and 12 strains of <I>Streptococcus</I> sp., 0.78 μg/ml for 6 strains of <I>Klebsiella pneumoniae</I>, 0.78 μg/ml for 4 strains of <I>Acinetobacter calcoaceticus</I>, ≤0.006 μg/ml for 16 strains of <I>Haemophilus</I> sp., 0.012 μg/ml for 4 strains of <I>Moraxella catarrhalis</I> and 3.13 μg/ml for 13 strains of <I>Pseudomonas aeruginosa</I>.<BR>GPFX was administered at a dose of 200 or 300 mg once/day for 7-14 days to 17 patients, including 3 cases of acute pneumonia, 4 cases of mycoplasma pneumonia, 1 case of acute bronchitis, 5 cases of chronic bronchitis, 1 case each of secondary infection to bronchiectasis and bronchial asthma, and 2 cases of secondary infection to pulmonary emphysema.<BR>The clinical results were excellent in 2 cases, effective in 12 cases, and slightly effective in 2 cases (excluding 1 patient who did not visit after the first consultation). Regardingthe dose distribution, all 6 cases in the 200 mg/day group and 8 of 10 cases in the 300 mg/day group responded effectively.<BR>The bacteriological results were as follows: 2 strains of isolated <I>H. influenzae</I>, 1 strain each of <I>M.catarrhalis</I>, <I>S. pneumoniae</I>, and <I>S. aureus</I> disappeared, and 1 strain of <I>P. aeruginosa</I> decreased.<BR>No side effects were observed in any of the patients. Abnormal laboratory findings were observed in 3 patients: a decrease in WBC in one and elevation of eosinophils in two.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.